Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 5/8/2020
SIETES contiene 93082 citas

 
 
 1 a 20 de 79 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Chao TF, Chiang CE, Chen TJ, Lip GYH, Chen SA. Reassessment of risk for stroke during follow-up of patients with atrial fibrillation. Ann Intern Med 2019:1 de enero. [Ref.ID 102996]
2.Tiene citas relacionadas Cita con resumen
Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, ten Berg JM, Steg PG, Hohnloser SH, for the RE-DUAL PCI Steering Committee and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017;377:1513-24. [Ref.ID 102099]
4.Tiene citas relacionadas Cita con resumen
Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GYH, Cohen M, Husted S, Peterson ED, Fox KA. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016;373:2423-34. [Ref.ID 101032]
5. Cita con resumen
Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J, Mercuri MF, Grosso MA, Fernandez V, Al-Saady N, Pelekh N, Merkely B, Zenin S, Kushnir M, Spinar J, Batushkin V, de Groot JR, Lip GYH, ENSURE-AF investigators. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet 2016;388:1995-2003. [Ref.ID 100910]
7.Enlace a cita originalTiene citas relacionadas Cita con resumen
Kotecha D, Manzano L, Krum H, Rosano G, Holmes J, Altman DG, Collins PD, Packer M, Wikstrand J, Coats AJS, Cleland JGF, Kirchhof P, von Lueder TG, Rigby AS, Andersson B, Lip GYH, van Veldhuisen DJ, Shibata MC, Wedel H, Böhm M, Flather MD, on behalf of the Beta-Blockers in Heart Failure Collaborative Group. Effect of age and sex on efficacy and tolerability of ß blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. BMJ 2016;352:i1855. [Ref.ID 100194]
8. Cita con resumen
Staerk L, Lip GYH, Olesen JB, Fosbol EL, Pallisgaard JL, Bonde AN, Gundlund A, Lindhardt TB, Hansen ML, Torp-Pedersen C, Gislason GH. Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. BMJ 2015;351:h5876. [Ref.ID 99694]
9.Tiene citas relacionadas Cita con resumen
Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GYH, Steeds RP, Townend J, Kotecha D. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ 2015;351:h4451. [Ref.ID 99419]
10. Cita con resumen
Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen H, Larsen TB, Lip GYH. Assessment of the CHA2DS2-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation. JAMA 2015;314:8 de septiembre. [Ref.ID 99418]
11. Cita con resumen
Navarese EP, Andreotti F, Schulze V, Kolodziejczak M, Buffon A, Brouwer M, Costa F, Kowalewski M, Parati G, Lip GYH, Kelm M, Valgimigli M. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ 2015;350:h1618. [Ref.ID 98975]
12. Cita con resumen
Lip GYH, Skjoth F, Rasmussen LH, Larsen TB. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol 2015;65:1385-94. [Ref.ID 98892]
13. Cita con resumen
Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JGF, Lip GYH, Coats AJS, Andersson B, Kirchhof P, von Lueder TG, Wedel H, Rosano G, Shibata MC, Rigby A, Flather MD, on behalf of the Beta-Blockers in Heart Failure Collaborative Group. Efficacy of ß blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 2014;384:2235-43. [Ref.ID 98435]
14. Cita con resumen
Lamberts M, Lip GYH, Hansen ML, Lindhardsen J, Olesen JB, Raunso J, Schjerning Olsen A-M, Andersen PK, Gerds TA, Nat R, Fosbol EL, Torp-Pedersen C. Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: a nationwide cohort study. Ann Intern Med 2014;161:690-8. [Ref.ID 98326]
15.Tiene citas relacionadas
Schlitt A, Rubboli A, Airaksinen KEJ, Lip GYH. Antiplatelet therapy and anticoagulants. Lancet 2013;382:24-5. [Ref.ID 95786]
16.Tiene citas relacionadas Cita con resumen
Roldán V, Marín F, Fernández H, Manzano-Fernández S, Gallego P, Valdés M, Vicente V, Lip GYH. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real world" population with atrial fibrillation receiving anticoagulant therapy. Chest 2013;143:179-84. [Ref.ID 94638]
17. Cita con resumen
18.Tiene citas relacionadas Cita con resumen
Homma S, Thompson JLP, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR, Ammon SE, Graham S, Sacco RL, Mann DL, Mohr JP, Massie BM, Labovitz AJ, Anker SD, Lok DJ, Ponilowski P, Estol CJ, Lip GYH, Di Tullio M, Sanford AR, Meija V, Grabriel AP, del Valle ML, Buchsbaum R, for the WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012;366:1859-69. [Ref.ID 92982]
19.Tiene citas relacionadas
Olesen JB, Lip GYH, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O, Olsen AMS, Gislason GH, Torp-Pedersen C. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011;342:320. [Ref.ID 90162]
20. Cita con resumen
Connolly SJ, Eikelboom J, Joyner C, Diener H-C, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Parkhomenko R, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GYH, Kim JH, Lanas-Zanetti F, González-Hermosillo A, Dans AL, Munawar M, for the AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17. [Ref.ID 90023]
Seleccionar todas
 
 1 a 20 de 79 siguiente >>